Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.34 |
| ▸ | SPR | P35270 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | CTSC | P53634 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29577611 | 0.83 | JAK1 (0.45) | USP30 | |
| SCHEMBL21457806 | 0.83 | JAK1 (0.45) | USP30 | |
| SCHEMBL19210943 | 0.80 | TSHR (0.45) | USP30MAPTTSHR | |
| SCHEMBL19211049 | 0.80 | RARA (0.36) | USP30MAPTMAOBACACB | |
| SCHEMBL19210897 | 0.77 | FFAR4 (0.41) | RORCNOTUMCTSKCTSC | |
| SCHEMBL19210893 | 0.77 | CTSC (0.41) | RORCUSP30NOTUMCTSKCTSC | |
| SCHEMBL19212302 | 0.76 | USP28 (0.39) | RORCNOTUMCTSKCTSCACACB | |
| SCHEMBL19096963 | 0.74 | DGAT1 (0.41) | — | |
| SCHEMBL19096981 | 0.74 | DGAT1 (0.41) | — | |
| SCHEMBL18155089 | 0.73 | IP6K1 (0.41) | NOTUMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3414252-B1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO HEALTH INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11325917-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2022-05-10 | — | — | US | disclosed |
| US-20210047343-A1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | VALO HEALTH, INC. | 2021-02-18 | — | — | US | disclosed |
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| US-10889592-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | VALO EARLY DISCOVERY, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| EP-3414251-B1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS INC (US) | 2019-10-16 | — | — | EP | disclosed |
| EP-3414251-A1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| EP-3414252-A1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | Forma Therapeutics, Inc. (US) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017139778-A1 | THIENOPYRIDINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017139779-A1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | FORMA THERAPEUTICS, INC. (US) | 2017-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047343-A1 | THIENOPYRAZINE CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS | USP25, USP28, USP30 | PRKDC 1948/4885RORC 1066/4885USP30 3/4885 |
| US-11325917-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | USP25, USP28, USP30 | PRKDC 1948/4885RORC 1066/4885USP30 3/4885 |
| US-10913753-B2 | Thienopyridine carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | PRKDC 1413/4885RORC 1116/4885USP30 4/4885 |
| US-10889592-B2 | Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors | USP25, USP28, USP30 | PRKDC 1948/4885RORC 1066/4885USP30 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.